Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus trial;...

Related Keywords

United Kingdom ,United States ,London ,City Of ,Stevenage ,Hertfordshire ,American ,Julia Wilson ,June Dec ,Susana Noonan ,Olivia Manser ,Ravi Rao ,Johnh Johnson ,European Medicines Agency ,University College London ,European Hematology Association ,Cardinal Health ,Nature Communications ,Sa Noonan Communications ,American Society Of Clinical Oncology ,Nasdaq ,Exchange Commission ,Ferrari ,Lupus Erythematosus ,Authorization Application ,Christian Itin ,Chief Executive Officer ,Systemic Lupus Erythematosus ,B Cell Acute Lymphoblastic Leukemia ,Biologics License Application ,American Society ,Clinical Oncology ,Multiple Myeloma ,Importation Authorization ,Marketing Authorization Application ,Mike Bonney ,Non Executive Director ,Structure Guided Engineering ,Nat Commun ,Blood Cancer Journal ,Dualt Cell ,Blood Cancer ,News Flow ,Quarter Ended March ,Unaudited Condensed Consolidated Statements ,Comprehensive Loss ,Months Ended March ,Autolus Therapeutics ,Private Securities Litigation Reform Act ,Autolu Annual Report ,